Skip to main content
. 2021 Jan 28;8:577125. doi: 10.3389/fcell.2020.577125

Figure 6.

Figure 6

Differential putative chemotherapeutic and immunotherapeutic response. (A) The immune prognostic model (IPM)-low group has a more promising response to anti-CTLA-4 therapy (Bonferroni corrected P = 0.005). (B) IPM-low group is more sensitive to targeted drugs.